When minutes matter for a patient’s care, what is AI’s role in clinical practice? Elad Walach, co-founder and CEO of Aidoc — a company with a comprehensive AI health care platform that analyzes real-time images and flags time-sensitive findings — shares his perspective on AI’s transformative power in dodging diagnostic error, improving access to care, and ensuring care quality in busy clinical settings.

Nineteen percent of adolescents experience moderate to severe anxiety and 2 million have a substance use disorder. This analysis covers the latest data on adolescent mental illness, suicide and drug overdose trends, and access to care.

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.

A new KFF tracker highlights key federal policy actions during President Trump’s second term that concern issues related to mental health and substance use. The second Trump administration has emphasized law-and-order strategies and scaled back several mental health and substance use-related services, while also continuing some treatment-focused initiatives. The tracker can be viewed in multiple ways, including chronological order of policy actions and by category (Mental Health; Opioids/Substance Use Disorder; Federal Infrastructure/ Data/Guidance; and Gun Violence).

This poll finds that less than half of the public now wants the U.S. to play at least a major role in improving the health of people in developing countries. When asked about the administration’s changes to foreign aid and global health, more people perceive a negative impact than a positive one.

This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on model details that are confidential or uncertain at this time.

This page displays an interactive map of the current status of state decisions on the Affordable Care Act's Medicaid expansion. Additional Medicaid expansion resources are listed (with links) below the map.

This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the other pending litigation involving mifepristone, and the mounting tension between states seeking to protect abortion and the states banning the provision of abortion.

Amid the growing use of artificial intelligence (AI) in the claims review cycle, this brief discusses the types of consumer protections for use of AI in prior authorization and claims review, describes the Trump administration’s general approach to AI , and highlights areas to watch as Congress considers AI legislation.

Drawing on KFF's poll findings, this interactive dashboard tracks the public’s trusted sources for health information, attitudes toward vaccines, and use of news, social media, and AI for health-related information. It provides visual representations of the key trends in the public’s trust in health information and tracks exposure to and belief in false and unproven health claims.

This KFF Health Tracking Poll finds that the cost of health care is a more prominent focus for Make America Healthy Again (MAHA) voters than issues like food and vaccine policy. Four in ten MAHA voters (42%) choose lowering health costs as the most important health priority, outranking other MAHA priorities.

Chemical food additive and pesticide concerns associated with the Make America Health Again (MAHA) movement are shared broadly across the public. But when it comes to voters, health care costs are a higher priority and bigger motivator, even among MAHA supporters, a new KFF Health Tracking Poll finds.

This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.

The data is good enough, the technology is getting better, the computing is becoming more available, and the use cases are getting clearer—but is AI truly a revolutionary technological advancement yet for health care? With a 30-year perspective on what digital technology has done and failed to do in health care, Dr. John Halamka, President of the Mayo Clinic Platform, joins Chip in discussing whether AI is actually disruptive or another wave of incremental change.

In 2024, the overall uninsured rate increased for the first time since 2019 as pandemic-era continuous enrollment in Medicaid came to an end, with significant increases among Hispanic, Black, and White people under age 65. These coverage losses were largely driven by the expiration of policies to stabilize and expand access to affordable coverage that were implemented during the COVID-19 pandemic.